• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非肌肉浸润性膀胱癌:指南并排比较。

Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.

机构信息

Department of Urology, University of Colorado, Denver, CO, USA.

出版信息

Eur Urol Focus. 2023 Nov;9(6):954-956. doi: 10.1016/j.euf.2023.05.004. Epub 2023 Jun 10.

DOI:10.1016/j.euf.2023.05.004
PMID:37308343
Abstract

Clinical guidelines from the European Association of Urology, American Urological Association, Society of Urologic Oncology, and National Comprehensive Cancer Network are some of the most frequently accessed publications. These guidelines are published at varying frequency and use different methods to formulate their recommendations. Many guidelines still rely on expert opinion in areas where there is a lack of data. To be well executed guidelines they need to involve comprehensive panels who are content experts and multispecialty. This article reviews the strengths and weaknesses of current guidelines for non-muscle-invasive bladder cancer and possible opportunities for future improvements. PATIENT SUMMARY: Quality recommendations in guidelines are critical to provide the most effective care for patients with non-muscle-invasive bladder cancer.

摘要

欧洲泌尿外科学会、美国泌尿外科学会、泌尿肿瘤学会和国家综合癌症网络的临床指南是最常被访问的出版物之一。这些指南的发布频率不同,制定建议的方法也不同。许多指南在数据不足的领域仍然依赖专家意见。为了制定出高质量的指南,它们需要涉及到全面的、多学科的专家小组。本文综述了目前非肌层浸润性膀胱癌指南的优缺点,以及未来可能的改进机会。患者总结:指南中的质量推荐对于为非肌层浸润性膀胱癌患者提供最有效的护理至关重要。

相似文献

1
Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.非肌肉浸润性膀胱癌:指南并排比较。
Eur Urol Focus. 2023 Nov;9(6):954-956. doi: 10.1016/j.euf.2023.05.004. Epub 2023 Jun 10.
2
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
3
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌(Ta、T1和原位癌)指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
4
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
5
Update on the guideline of guidelines: non-muscle-invasive bladder cancer.指南更新:非肌肉浸润性膀胱癌。
BJU Int. 2020 Feb;125(2):197-205. doi: 10.1111/bju.14915. Epub 2019 Nov 1.
6
European Association of Urology and American Urological Association/Society of Urologic Oncology Guidelines on Risk Categories for Non-muscle-invasive Bladder Cancer May Lead to Overtreatment for Low-grade Ta Bladder Tumors.欧洲泌尿外科学会与美国泌尿外科学会/泌尿肿瘤学会关于非肌层浸润性膀胱癌风险分类的指南可能导致低级别Ta期膀胱肿瘤的过度治疗。
Urology. 2017 Jul;105:14-17. doi: 10.1016/j.urology.2017.03.034. Epub 2017 Mar 30.
7
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南:2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
8
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2013 年更新版。
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
9
External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.欧洲癌症研究与治疗组织及西班牙肿瘤治疗泌尿学俱乐部评分模型的外部验证,用于预测接受卡介苗治疗的日本非肌层浸润性膀胱癌患者的复发和进展情况。
Int J Urol. 2014 Dec;21(12):1201-7. doi: 10.1111/iju.12572. Epub 2014 Jul 30.
10
Guideline of guidelines: non-muscle-invasive bladder cancer.指南之指南:非肌层浸润性膀胱癌
BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24.

引用本文的文献

1
Comparative efficacy of holmium laser versus plasma techniques in the surgical management of non-muscle invasive bladder cancer: a meta-analysis.钬激光与等离子技术在非肌层浸润性膀胱癌手术治疗中的疗效比较:一项荟萃分析。
Front Oncol. 2025 Aug 6;15:1625901. doi: 10.3389/fonc.2025.1625901. eCollection 2025.
2
Chemotherapeutic dihydromyricetin with remarkable anti-tumor activity and biosafety for muscle invasive bladder cancer.具有显著抗肿瘤活性且对肌肉浸润性膀胱癌具有生物安全性的化疗药物二氢杨梅素。
Front Pharmacol. 2025 Jul 18;16:1609354. doi: 10.3389/fphar.2025.1609354. eCollection 2025.
3
Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer.
年龄较小和充足的卡介苗(BCG)是提高非肌肉浸润性膀胱癌 BCG 治疗效果的关键因素。
World J Urol. 2024 Sep 27;42(1):547. doi: 10.1007/s00345-024-05218-4.
4
Identification of ECM and EMT relevant genes involved in the progression of bladder cancer through bioinformatics analysis.通过生物信息学分析鉴定参与膀胱癌进展的细胞外基质(ECM)和上皮-间质转化(EMT)相关基因。
Am J Clin Exp Urol. 2024 Aug 25;12(4):183-193. doi: 10.62347/XNTC7030. eCollection 2024.